Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer

Volume: 8, Issue: 1
Published: Feb 21, 2018
Abstract
Carbohydrate antigen (CA) 19-9 is the only diagnostic marker used in pancreatic cancer despite its limitations. Here, we aimed to identify the diagnostic role of CEMIP (also called KIAA1199) combined with CA 19-9 in patients with pancreatic cancer. A retrospective analysis of prospectively collected patient samples was performed to determine the benefit of diagnostic markers in the diagnosis of pancreatic cancer. We investigated CEMIP and CA...
Paper Details
Title
Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer
Published Date
Feb 21, 2018
Volume
8
Issue
1
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.